Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

171.09 -4.65 (-2.65%)

Streaming Delayed Price Updated: 10:14 AM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

56 57 Next >

Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23 ↗

March 23, 2023

Looking for longs after a clear resumption of the uptrend.

Via Talk Markets

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗

March 23, 2023

The companies are focusing on a small population of ALS patients with a genetic mutation.

Via Investor's Business Daily

FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗

March 23, 2023

Via Benzinga

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

March 22, 2023

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States

From Biogen Inc.

Via GlobeNewswire

iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach ↗

March 22, 2023

Interested in investing in iMetabolic BioPharma? Click here to get started!

Via Benzinga

Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit ↗

March 21, 2023

Via Benzinga

Should You Buy Biogen Before a Big July Decision? ↗

March 19, 2023

Biogen stock has dropped about 40% from its record high.

Via The Motley Fool

Price Over Earnings Overview: Biogen ↗

March 17, 2023

Via Benzinga

7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

March 17, 2023

Via Benzinga

Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year ↗

March 16, 2023

Via Benzinga

Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments ↗

March 16, 2023

Via Benzinga

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

March 16, 2023

From Biogen Inc.

Via GlobeNewswire

Biogen's Debt Overview ↗

March 15, 2023

Via Benzinga

Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

March 15, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...

Via FinancialNewsMedia

Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity ↗

March 14, 2023

Via Benzinga

Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3

March 14, 2023

Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,

Via MarketBeat

1 Reason to Buy Biogen Stock, and 1 Reason to Sell ↗

March 14, 2023

It could be a make or break year for the biotech.

Via The Motley Fool

Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval ↗

February 28, 2023

The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys.

Via Investor's Business Daily

Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone ↗

March 13, 2023

Via Benzinga

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed ↗

March 09, 2023

The company is definitively closing the door on solanezumab.

Via Investor's Business Daily

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock ↗

March 09, 2023

Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.

Via InvestorPlace

Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8 ↗

March 08, 2023

Looking for a bottom in wave {v} to then look for longs.

Via Talk Markets

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

March 08, 2023

From Biogen Inc.

Via GlobeNewswire

Why Shares of Anavex Life Sciences Rose 12.4% in February ↗

March 06, 2023

The company's first-quarter earnings report detailed positive news regarding its pipeline.

Via The Motley Fool

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment ↗

March 06, 2023

Via Benzinga

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

March 05, 2023

From Biogen Inc.

Via GlobeNewswire

What Does Biogen's Debt Look Like? ↗

March 02, 2023

Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...

Via Benzinga

Peering Into Biogen's Recent Short Interest ↗

March 01, 2023

Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that...

Via Benzinga

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.